Publications
226
Citations
3,264
Est. group size
~25
Recurring co-author estimate
Active years
39
Publishing since 1988
Marcelo Bonomi's research focuses on head and neck cancers, especially squamous cell carcinoma, including how immune-based drugs (like immune checkpoint inhibitors and cetuximab) work in combination with chemotherapy and radiation. His work spans clinical trials, biomarker discovery (such as circulating tumor DNA and T-cell profiling), and outcomes research using tools like whole slide imaging and AI to predict treatment response. This research is aimed at improving survival and treatment decisions for patients with recurrent or metastatic head and neck cancers.
Publication output has grown substantially over the last decade, rising from single digits annually in 2017-2019 to a peak of over 30 papers per year in 2023-2024, with continued high output into 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Comment on: Fully <scp>COVID</scp> ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head & Neck · 2026
- Supplementary Tables1 from Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer
2026
- Data from Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer
2026
- Supplementary Data1 from Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer
2026
- Enrichment of Cancer Associated Fibroblasts in Radiation-Treated Recurrent Olfactory Neuroblastoma
Journal of Neurological Surgery Part B Skull Base · 2026
- Impact of Treatment Package Time on Survival in Patients with Head and Neck Adenoid Cystic Carcinoma
Cancers · 2026
- Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer
JCO oncology advances. · 2026
- Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer
JAMA Otolaryngology–Head & Neck Surgery · 2026
- Abstract 3871: Molecular correlates of response and survival in a phase II trial of weekly carboplatin/paclitaxel plus cemiplimab (wCP+C) in advanced/metastatic mucosal head and neck squamous cell carcinoma (a/mHNSCC).
Cancer Research · 2026
- Second-line cetuximab plus immune checkpoint inhibitor (ICI) versus cetuximab plus carboplatin and paclitaxel following ICI-containing regimen in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Journal of Clinical Oncology · 2026
- Cytokine dynamics in a phase II trial of metronomic carboplatin/paclitaxel combined with cemiplimab in recurrent/metastatic head and neck squamous cell carcinoma.
Journal of Clinical Oncology · 2026
- Whole slide imaging–based prediction of immunohistochemistry markers and surgical pathological features.
Journal of Clinical Oncology · 2026
- Multimodal AI prediction of head and neck cancer treatment outcomes with whole slide imaging.
Journal of Clinical Oncology · 2026
- Association of pre-treatment hemoglobin level as a prognostic factor for survival outcomes in head and neck cancer patients treated with definitive radiation.
Journal of Clinical Oncology · 2026
- Predictors of persistent opioid use following curative-intent radiation for head and neck cancer.
Journal of Clinical Oncology · 2026
- Journal of Clinical Oncology×26
- International Journal of Radiation Oncology*Biology*Physics×25
- Annals of Oncology×10
- Cancers×8
- Journal of Neurological Surgery Part B Skull Base×6
- Priyanka Bhateja
Medicine · The Ohio State University
- James W. Rocco
Medicine · The Ohio State University
- Darrion Mitchell
Medicine · The Ohio State University
- Lingbin Meng
Medicine · The Ohio State University
- Tyler Haddad
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile